Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor

US10428083B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Michael Härter · Wixom, US
• Dirk Kosemund · Berlin, DE
• Martina Delbeck · Essen, DE
• Bernd Kalthof · Wuppertal, DE
• Pierre Wasnaire · Mülheim an der Ruhr, DE
• Frank Süβmeier · Birkenfeld, DE
• Klemens Lustig · Wuppertal, DE

Key dates

• Filing date: Mar 21, 2016
• Grant date: Oct 1, 2019
• Expiry date: Mar 21, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.